BR112019005113A2 - composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível a sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. - Google Patents
composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível a sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.Info
- Publication number
- BR112019005113A2 BR112019005113A2 BR112019005113A BR112019005113A BR112019005113A2 BR 112019005113 A2 BR112019005113 A2 BR 112019005113A2 BR 112019005113 A BR112019005113 A BR 112019005113A BR 112019005113 A BR112019005113 A BR 112019005113A BR 112019005113 A2 BR112019005113 A2 BR 112019005113A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- suffer
- treating
- stability
- improving
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940071648 metered dose inhaler Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 238000010792 warming Methods 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 229940092705 beclomethasone Drugs 0.000 abstract 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- -1 beclomethasone compound Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
trata-se de uma composição farmacêutica. a composição compreende: (i) um componente de fármaco que compreende pelo menos um composto de beclometasona selecionado entre a beclometasona e os derivados farmaceuticamente aceitáveis da mesma e pelo menos um agonista beta-2 de longa duração; (ii) um componente propulsor que compreende 1,1-difluoroetano (hfa-152a); e (iii) glicerol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615908.9A GB2554088A (en) | 2016-09-19 | 2016-09-19 | Pharmaceautical composition |
| GBGB1620515.5A GB201620515D0 (en) | 2016-12-02 | 2016-12-02 | Pharmaceutical composition |
| PCT/GB2017/052762 WO2018051131A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005113A2 true BR112019005113A2 (pt) | 2019-06-04 |
Family
ID=59997387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005113A BR112019005113A2 (pt) | 2016-09-19 | 2017-09-18 | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível a sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190388436A1 (pt) |
| EP (3) | EP3610877A1 (pt) |
| JP (2) | JP6781832B2 (pt) |
| KR (1) | KR102279445B1 (pt) |
| CN (3) | CN109789151A (pt) |
| AU (2) | AU2017328908B2 (pt) |
| BR (1) | BR112019005113A2 (pt) |
| CA (1) | CA3037257C (pt) |
| CO (1) | CO2019002555A2 (pt) |
| EA (1) | EA201990501A1 (pt) |
| ES (1) | ES2841649T5 (pt) |
| GE (1) | GEP20217240B (pt) |
| IL (1) | IL265349B2 (pt) |
| MX (1) | MX2019003103A (pt) |
| MY (1) | MY202030A (pt) |
| PE (1) | PE20191044A1 (pt) |
| PH (1) | PH12019500577A1 (pt) |
| UA (1) | UA124240C2 (pt) |
| WO (1) | WO2018051131A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3036628C (en) * | 2016-09-19 | 2021-11-16 | Mexichem Fluor S.A. De C.V. | Pharmaceutical compositions comprising tiotropium bromide monohydrate and 1,1-difluoroethane |
| WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
| GB2586477A (en) * | 2019-08-20 | 2021-02-24 | Mexichem Fluor Sa De Cv | Composition and method |
| EP4069189A1 (en) | 2019-12-02 | 2022-10-12 | Chiesi Farmaceutici S.p.A. | Stainles steel can for pressurised metered dose inhalers |
| KR20220133193A (ko) | 2020-01-28 | 2022-10-04 | 키에시 파르마슈티시 엣스. 피. 에이. | 완충된 약제학적 제제를 포함하는 가압 정량 흡입기 |
| US20230080276A1 (en) | 2020-02-20 | 2023-03-16 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| BR9812693A (pt) | 1997-09-29 | 2000-08-22 | Inhale Therapeutic Syst | Uso de um agente bioativo, processo para formar uma microestrutura perfurada, microestrutura perfurada, processo para aumentar a dispersibilidade de um pó, pó de microestrutura perfurada, pó tendo dispersibilidade aumentada, sistema de inalação para a administração pulmonar de um agente bioativo a um paciente, e, processo para a liberação pulmonar de um ou mais agentes bioativos |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2003303029A1 (en) * | 2002-12-16 | 2004-07-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing hfc solution formulations |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| EP2627325A1 (en) * | 2010-10-12 | 2013-08-21 | Cipla Limited | Pharmaceutical composition |
| MX2013009525A (es) * | 2011-02-17 | 2013-10-01 | Cipla Ltd | Combinacion de glicopirrolato y un beta2-agonista. |
| GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| BR112015006571A2 (pt) * | 2012-10-23 | 2017-07-04 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| CA3007050C (en) * | 2015-12-04 | 2020-12-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition comprising a formoterol compound |
| CA3036628C (en) * | 2016-09-19 | 2021-11-16 | Mexichem Fluor S.A. De C.V. | Pharmaceutical compositions comprising tiotropium bromide monohydrate and 1,1-difluoroethane |
| CN114515284A (zh) * | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
-
2017
- 2017-09-18 AU AU2017328908A patent/AU2017328908B2/en active Active
- 2017-09-18 MY MYPI2019001314A patent/MY202030A/en unknown
- 2017-09-18 CA CA3037257A patent/CA3037257C/en active Active
- 2017-09-18 ES ES17777636T patent/ES2841649T5/es active Active
- 2017-09-18 CN CN201780057285.4A patent/CN109789151A/zh active Pending
- 2017-09-18 GE GEAP201715034A patent/GEP20217240B/en unknown
- 2017-09-18 US US16/334,156 patent/US20190388436A1/en active Pending
- 2017-09-18 CN CN202310774818.8A patent/CN116898804A/zh active Pending
- 2017-09-18 EP EP19199776.6A patent/EP3610877A1/en active Pending
- 2017-09-18 EP EP17777636.6A patent/EP3515451B2/en active Active
- 2017-09-18 MX MX2019003103A patent/MX2019003103A/es unknown
- 2017-09-18 WO PCT/GB2017/052762 patent/WO2018051131A1/en active Application Filing
- 2017-09-18 JP JP2019515271A patent/JP6781832B2/ja active Active
- 2017-09-18 BR BR112019005113A patent/BR112019005113A2/pt active Search and Examination
- 2017-09-18 EP EP19199786.5A patent/EP3607951A1/en active Pending
- 2017-09-18 CN CN202110273940.8A patent/CN113069417A/zh active Pending
- 2017-09-18 IL IL265349A patent/IL265349B2/en unknown
- 2017-09-18 KR KR1020197010383A patent/KR102279445B1/ko active IP Right Grant
- 2017-09-18 UA UAA201902773A patent/UA124240C2/uk unknown
- 2017-09-18 PE PE2019000675A patent/PE20191044A1/es unknown
- 2017-09-18 EA EA201990501A patent/EA201990501A1/ru unknown
-
2019
- 2019-03-18 PH PH12019500577A patent/PH12019500577A1/en unknown
- 2019-03-19 CO CONC2019/0002555A patent/CO2019002555A2/es unknown
- 2019-09-25 US US16/582,964 patent/US20200016175A1/en active Pending
- 2019-09-25 US US16/582,710 patent/US20200016174A1/en active Pending
-
2020
- 2020-03-11 JP JP2020042092A patent/JP6980050B2/ja active Active
- 2020-04-20 AU AU2020202651A patent/AU2020202651C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005113A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível a sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| BR112019005133A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| BR112019005168A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica | |
| BR112019005120A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhorar o desempenho de dispersão em aerossol após armazenamento de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| BR112018011266A2 (pt) | ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica? | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| CL2017001859A1 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol | |
| BR112014008602A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| BR112015026053A8 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112019008239A2 (pt) | formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| BR112019005080A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
| BR112022010360A2 (pt) | Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |